9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

Estimated reading time: < 1 min

Condition: Leukemia

Estimated Enrollment: 22

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: Has Results

Outcome Measures: Safety,  Immune Response,  ,

Interventions: WT-1 analog peptide vaccine, incomplete Freund’s adjuvant

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: June 2009

Completion Date: June 2009

Last  Posted Date: March 2, 2016

Location: Memorial Sloan Kettering Cancer Center, New York, New York, United States

Website Link: https://ClinicalTrials.gov/show/NCT00398138

Was this article helpful?
Dislike 0